[1]
Mystakidou, MD, PhD, K., Katsouda, MD, E., Parpa, BA, MA, E., Tsiatas, MD, PhD, M.L. and Vlahos, MD, PhD, L. 2005. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics. Journal of Opioid Management. 1, 1 (Mar. 2005), 36–40. DOI:https://doi.org/10.5055/jom.2005.0010.